RPEP-15435 · 2026Intestinal IL-22 enhances L-cell GLP-1 production via STAT3 pathway, improving glucose metabolism and mechanistically linking gut immunity to incretin hormone secretion.
Kim, Chae-Won; Ahn, Jae-Hee; Lee, Bo Ra; Kim, Hong Min; Han, Youngjoo; Jeong, Jae-Hyeon; Cho, Jaewon; Jeong, Hyunjin; Kim, Dae-Joon; Kim, Seong-Eun; Kim, Jeon-Kyung; Lee, Yu-Bin; Kim, Su Min; Yoo, Hye Hyun; Lee, Eun Hye; Seo, Su Ryeon; Ha, Kyung Bong; Lee, Eun Soo; Kweon, Mi-Na; Kim, Hong Pyo; Chang, Sun-Young; Chung, Choon Hee; Ko, Hyun-Jeong ·
RPEP-15436 · 2026GLP-1 RA cardioprotection: clinically proven (MACE reduction) but mechanistically incomplete. Anti-inflammatory effects likely central; specific molecular pathways between inflammation modulation and CV outcomes unclear.
Kim, Ellis Y; Feinstein, Matthew J ·
RPEP-15437 · 2026Myoki peptide: multi-mechanism anti-atrophy action including protein synthesis promotion, degradation inhibition, and satellite cell activation for muscle preservation.
Kim, Eun Mi; Kim, Seon Soo; Hyun, Yong Geon; Lee, Su Yeon; Chung, Yong Ji ·
RPEP-15438 · 2026CPP design evolution: computational/AI design, stimulus-responsive activation (pH/enzyme/light), and targeting modifications enabling precise, cell-type-specific drug delivery with reduced off-target effects.
Kim, Eun-Ji; Lee, Yuna; Ryu, Juhee; Kim, Hyemin; Park, Juhee; Lee, Jiyoun ·
RPEP-15439 · 2026Peptide antimicrobials approaching clinical viability through AI design, stability engineering, delivery innovations, and hybrid approaches, with several candidates in late-stage development.
Kim, Hyo Jung ·
RPEP-15440 · 2026Ultrasound actuated neuropeptide delivery across cerebrovascular interfaces, demonstrating non-invasive, region-specific brain-targeted peptide therapeutics.
Kim, Inhye; Griffith, Keith; Brockway, Dakota F; Crowley, Nicole A; Medina, Scott H ·
RPEP-15441 · 2026Perioperative GLP-1 RA use: reduced revision surgery and complications after spinal fusion, supporting anti-inflammatory and osteogenic benefits for surgical healing.
Kim, Matthew T; Lee, Seungjun; Goh, Graham S; Riew, K Daniel ·
RPEP-15442 · 2026Oral semaglutide: improved survival in HFpEF + T2D patients, extending injectable semaglutide's heart failure benefits to oral formulation.
Kishimori, Takefumi; Kato, Takao; Iwasaki, Yoshihiro; Shimada, Takenobu; Wada, Atsuyuki; Tani, Akira; Yamaji, Ryosuke; Koike, Jumpei; Matsumoto, Takehiro; Yagi, Takafumi; Okada, Masaharu ·
RPEP-15443 · 2026Baseline fecal microbiome composition predicted semaglutide treatment response, with specific bacterial signatures distinguishing responders from non-responders before treatment initiation.
Klemets, Annabel; Reppo, Ingrid; Krigul, Kertu Liis; Volke, Vallo; Aasmets, Oliver; Org, Elin ·
RPEP-15444 · 2026Co-administered iRGD peptide enhanced anti-PD-L1 therapy in HCC: improved antibody tumor penetration, increased T cell infiltration, overcame immunosuppressive TME, and significantly outperformed anti-PD-L1 alone.
Klug, Jan Henrik; Aliraj, Blerina; Alcober-Boquet, Lucia; Denk, Dominic; Germann, Lena; Meindl-Beinker, Nadja M; De La Torre, Carolina; Waidmann, Oliver; Finkelmeier, Fabian; Zeuzem, Stefan; Brüne, Bernhard; Vogl, Thomas J; Weigert, Andreas; Piiper, Albrecht ·
RPEP-15445 · 2026GLP-1 RAs and dual agonists: reduced obesity-related cancer risk vs other diabetes medications in large population analysis.
Ko, Albert; Chang, Yu-Cheng; Bahar, Furkan; Wang, Tsu Hsien; Xanthavanij, Nutchapon; Yu, Chun-Chiao; Hsieh, Rebecca Jen-Ling; See, Xin Ya; Lo, Shao-Wei; Song, Junmin; Hsia, Yuan Ping; Chiang, Cho-Hung; Xu, Xiaocao; Lin, Shuwen; Chiang, Cho-Han ·
RPEP-15446 · 2026177Lu-oxodotreotide PRRT: long-term efficacy and acceptable safety confirmed in Japanese NET patients, consistent with global PRRT data.
Kobayashi, Noritoshi; Ono, Hiroaki; Okubo, Naoki; Akahoshi, Keiichi; Kudo, Atsushi; Ban, Daisuke; Ichikawa, Yasushi ·
RPEP-15447 · 2026Second-generation incretin therapies risk micronutrient deficiencies (B12, D, iron, folate) through reduced intake and potential malabsorption, requiring proactive monitoring not currently standard in GLP-1 prescribing.
Koceva, Andrijana; Janež, Andrej; Pečko, Tajda; Jensterle, Mojca ·
RPEP-15448 · 2026Animal venoms contain neuropeptide mimics (insulin, oxytocin, vasopressin, somatostatin analogs) evolved through molecular mimicry, providing naturally optimized drug design templates.
Koch, Thomas Lund; Safavi-Hemami, Helena ·
RPEP-15449 · 2026AN gut hormone alterations (elevated ghrelin, altered GLP-1/PYY/GIP) partially normalize with short-term refeeding, providing biomarkers for nutritional recovery assessment.
Kolb, Theresa; Licht, Louisa; Tam, Friederike I; Stender, Evelina M; Ohme, Michaela; Borsini, Alessandra; Ehrlich, Stefan; Perakakis, Nikolaos ·
RPEP-15450 · 2026Umbrella review confirms GLP-1 RA efficacy: glycemic control + weight loss + cardiovascular protection + renal outcomes + emerging indications, with consistent safety across all systematic reviews.
Kong, Fanjing; Zhao, Yanru; Zhang, Weiming; Wang, Xinyi; Wu, Tianyu; Zhou, Ziyi; Xu, Ying; Xia, Lina; Sun, Tao ·
RPEP-15451 · 2026AI agent-based design: D-enantiomeric AMPs active against MDR bacteria, combining complete protease resistance with potent antimicrobial activity without natural peptide templates.
Kong, Qingzhou; Zhao, Yinuo; Gong, Haifan; Kang, Luoyao; Fu, Jialu; Li, Lixiang; Wan, Boyao; Wang, Peizhu; Li, Xiaojuan; Wang, Yue; Zhang, Jinghui; Yu, Yanbo; Yang, Xiaoyun; Zuo, Xiuli; Wang, Haina; Li, Yanqing ·
RPEP-15452 · 2026Liraglutide: effective for NAFLD in both T2D and non-diabetic patients, reducing liver fat, inflammation, and fibrosis markers with acceptable safety across populations.
Kong, Weihan; Fang, Buwu; Xing, Wei ·
RPEP-15453 · 2026Dual diffusion model framework: generated AMPs with improved activity predictions through simultaneous sequence and activity representation learning, outperforming single-model approaches.
Kong, Wen; Fu, Lingling; Jiang, Xingpeng; Zhao, Weizhong ·
RPEP-15454 · 2026GLP-1 RA pancreatic effects may be biliary-mediated rather than direct pancreatic GLP-1R activation, reinterpreting the mechanism and potentially explaining pancreatitis safety signals.
Koren, Andro; Koren, Luciana ·
RPEP-15456 · 2026Comprehensive GLP-1 molecular mechanisms: receptor binding, G protein/β-arrestin dual signaling, biased agonism, and downstream pathways mediating metabolic, cardiovascular, and neuroprotective therapeutic effects.
Kowalska, Małgorzata Katarzyna; El-Mallul, Ahmed; Hudecka, Weronika; Lubojańska, Joanna Elżbieta; Lubojański, Piotr Jan; Orłowska, Sara Małgorzata; Bednarczyk, Łukasz ·
RPEP-15457 · 2026Peptide therapeutics for wounds: dual-action combining analgesic (opioid peptides, derivatives) and regenerative (growth factors, AMPs) properties for comprehensive wound management.
Kołodyńska, Klaudia; Kamysz, Wojciech; Kleczkowska, Patrycja ·
RPEP-15458 · 2026SGLT2i vs GLP-1 RA: differential cardiovascular outcome benefits in HF patients based on HF phenotype and comorbidity profile, informing personalized drug selection.
Kristensen, Frederik P B; Christensen, Diana H; Callaghan, Brian C; Nielsen, Jens S; Andersen, Henning; Sørensen, Henrik T; Thomsen, Reimar W ·
RPEP-15459 · 2026GIP/GLP-1 receptor antagonism in pancreatectomized patients revealed insulin-independent metabolic effects, demonstrating incretin actions beyond β-cell function.
Krogh, Liva S L; Helsted, Mads M; Englund, Anders; Bergmann, Natasha C; Skov-Jeppesen, Kirsa; Nielsen, Casper K; Hansen, Carsten P; Rosenkilde, Mette M; Hartmann, Bolette; Holst, Jens J; Knop, Filip K; Lund, Asger B; Gasbjerg, Lærke S ·
RPEP-15460 · 2026Caudate amphibian peptides: dual antioxidant and antimicrobial activities, expanding the bioactive peptide library beyond well-studied frog species to salamanders/newts.
Kröner, Lorena; Meier, Jutta; Hopp, Marie-T ·
RPEP-15461 · 2026Head-to-head cardiovascular outcome comparison of semaglutide vs tirzepatide in T2D patients, providing the first comparative CV data for these two leading incretin drugs.
Krüger, Nils; Schneeweiss, Sebastian; Desai, Rishi J; Sreedhara, Sushama Kattinakere; Kehoe, Anna R; Fuse, Kenshiro; Hahn, Georg; Schunkert, Heribert; Wang, Shirley V ·
RPEP-15462 · 2026Endogenous GIP signaling is required for DPP-4 inhibitor metabolic effects, demonstrating DPP-4 drugs work primarily through GIP preservation rather than GLP-1 preservation.
Kubota-Okamoto, Saki; Kubota, Sodai; Tsuchida, Hiromi; Liu, Yanyan; Banno, Seiya; Imaizumi, Toshinori; Fujisawa, Taro; Takahashi, Yoshihiro; Kato, Takehiro; Horikawa, Yukio; Iizuka, Katsumi; Murakami, Takaaki; Fujiwara, Yuuka; Kuwata, Hitoshi; Yamazaki, Yuji; Seino, Yutaka; Tsunekawa, Shin; Yabe, Daisuke ·
RPEP-15463 · 2026Four months of GLP-1 RA weight loss treatment associated with mental health improvements including reduced anxiety, depression, and improved quality of life.
Kuckuck, Susanne; van Gerwen, Nina; Oosterman, Johanneke E; Savas, Mesut; Kavousi, Maryam; Penninx, Brenda W J H; Boon, Mariëtte R; van Rossum, Elisabeth F C ·
RPEP-15464 · 202652-week extension: sustained oral semaglutide HbA1c and weight benefits with consistent safety and no new safety signals over extended treatment period.
Kudrow, David; Croop, Robert S; Thiry, Alexandra; Lipton, Richard B ·
RPEP-15465 · 2026Deep Q-Network with multi-view ensemble learning: improved anti-diabetic peptide prediction accuracy over single-view approaches, accelerating peptide-based diabetes therapeutic discovery.
Kumar, Aditya; Singh, Deepak ·
RPEP-15466 · 2026Salmonella AMP resistance: surface binding proteins intercept AMPs + lipid A modifications reduce membrane binding affinity. Molecular characterization informs AMP design to overcome these defenses.
Kumar, Rahul; Choubey, Akriti ·
RPEP-15467 · 2026GLP-1 RAs: established cardiovascular role with proven MACE reduction, HFpEF benefits, kidney protection, and emerging PAD/AF benefits — cardiovascular standard of care beyond diabetes.
Kumar, Sonal; Anderson, John E; Coviello, Andrea; Lopez-Jimenez, Francisco; Bakris, George L ·
RPEP-15468 · 2026N-terminal modified α/β-hybrid peptides: enhanced cancer vs normal cell selectivity + maintained antimicrobial activity through backbone engineering.
Kumari, Jyoti; Sarkar, Aminur Rahman; Rashid, Beenish; Rathore, Arti; Firdous, Shifa; Chowdhary, Rubina; Sarkar, Biplab; Manhas, Rakshit; Rai, Rajkishor; Mahapa, Avisek ·
RPEP-15469 · 2026Comprehensive GLP-1 RA safety review: GI (common, manageable), pancreatitis (monitoring), thyroid (reassuring), NAION (low absolute risk), bile duct (investigating), mental health (safe), musculoskeletal (variable). Evidence-based management for each.
Kunutsor, Setor K; Seidu, Samuel ·
RPEP-15470 · 2026PDCs, SMDCs, and novel conjugate modalities are emerging as ADC alternatives with advantages in tumor penetration, manufacturing simplicity, cost, and immunogenicity for targeted cancer therapy.
Kurtova, Anastasia I; Iureva, Anna M; Esetov, Nikolay S; Sokol, Daniil V; Fedotova, Polina A; Shipunova, Victoria O ·
RPEP-15471 · 2026Peptide-functionalized iron oxide NPs: multi-modal cancer therapy combining magnetic targeting, drug delivery, MRI imaging, and hyperthermia through peptide-guided tumor specificity.
Kuskov, Andrey N; Thrapsanioti, Lydia-Nefeli; Kukovyakina, Ekaterina; Yagolovich, Anne; Vlaskina, Elizaveta; Tzanakakis, Petros; Berdiaki, Aikaterini; Nikitovic, Dragana ·
RPEP-15472 · 2026GLP-1 RA treatment associated with CSU improvement, suggesting immunomodulatory effects on mast cell-driven inflammation and immune dysregulation beyond metabolic benefits.
Kwiek, Bartłomiej; Sieczych, Julia; Łukowska, Katarzyna; Ambroziak, Marcin ·
RPEP-15473 · 2026Optimized CXCR4-targeting peptide theranostic pair: improved tumor uptake and imaging quality for diagnostic PET + therapeutic radionuclide delivery in CXCR4-expressing cancers.
Kwon, Daniel; Bloise, Ingrid; Zhang, Zhengxing; Colpo, Nadine; Wilson, Ryan; Tan, Ruiyan; Merkens, Helen; Zeisler, Jutta; Lau, Joseph; Lin, Kuo-Shyan; Bénard, François ·
RPEP-15474 · 2026GLP-1 RAs for rheumatic diseases: weight reduction + immunomodulation could improve disease activity, joint outcomes, and drug effectiveness in RA, PsA, OA, and gout.
Kyriazi, Niki; Vassilakis, Konstantinos D; Bakiri, Amalia; Iliopoulos, Alexios; Fragoulis, George E ·
RPEP-15475 · 2026Self-assembling AMP prodrugs: spontaneous nanostructure formation providing stability, targeting, and controlled release without carrier materials — carrier-free AMP delivery revolution.
Ladaycia, Abdallah; Lemaire, Laurent; Pailhoriès, Hélène; Lautram, Nolwenn; Franconi, Florence; Pigeon, Pascal; Jaouen, Gérard; Passirani, Catherine; Lepeltier, Elise ·
RPEP-15476 · 2026Oral semaglutide: improved QoL alongside HbA1c, weight, and lipid improvements in real-world T2D patients — clinical and patient-centered benefits from daily pill.
Lago Garma, Javier; Gil Mouce, Cristina; Rodríguez Novo, Nazareth; Díaz Trastoy, Olaia; Santamaría Nieto, Alicia; Pérez Castro, Patricia; Díaz Ortega, Carmen; Fernández Rodríguez, Eva; Palmeiro Carballeira, Regina; Pinal Osorio, Iria; Prieto Tenreiro, Alma; Sánchez Sobrino, Paula; Tejera Pérez, Cristina; Pita Gutiérrez, Francisco; Villar Taibo, Rocío; Vidal Casariego, Alfonso ·
RPEP-15477 · 2026Traditional medicine venom peptides are being scientifically validated: confirmed anti-inflammatory, analgesic, anticancer, and antimicrobial activities bridging ancient practice with modern pharmacology.
Lai, Shian; Chai, Jinwei; Luo, Yongtao; Luo, Lei; Xu, Xueqing ·
RPEP-15478 · 2026IMNM (immune-mediated necrotizing myopathy) following semaglutide — rare autoimmune muscle adverse event requiring clinical awareness for unexplained weakness during GLP-1 therapy.
Lam, Brian; Tiniakou, Eleni; Zhang, Xinhai Robert; Assassi, Shervin ·
RPEP-15479 · 2026GLP-1 RAs: effective and safe for hypothalamic obesity in craniopharyngioma patients, addressing a condition with essentially no prior effective treatments.
Lambert, Flora; Guillon, Emilie; Gatta-Cherifi, Blandine; Soula, Hedi; Poitou, Christine; Faucher, Pauline ·
RPEP-15480 · 2026SP protected against colitis and anxiety-like behavior through gut-brain axis modulation, challenging its traditional pro-inflammatory characterization and revealing protective roles in IBD.
Lan, Jing; Wang, Jiaqi; Huang, Sijuan; Li, Chenyu; Deng, Ziteng; Hao, Zhihui; Ma, Yunfei ·
RPEP-15481 · 2026Enzyme-mediated poly(Tyr-co-Phe) hydrogel: prolonged IL-10 release for sustained anti-inflammatory immune modulation from a biodegradable amino acid-based material.
Landa-Tencle, Fátima; Hernández-Valencia, Carmen G; Guzmán-Lagunes, Fernando; Montiel, Carmina; Cuellar-Entenza, Yoan; Guerrero-Sánchez, Carlos; Stumpf, Steffi; Hoeppener, Stephanie; Schubert, Ulrich S; Zamudio-Cuevas, Yessica; Sánchez-Sánchez, Roberto; Gimeno, Miquel ·
RPEP-15482 · 2026Two adults with acquired hypothalamic obesity achieved significant weight loss with GLP-1 drug therapy, demonstrating non-hypothalamic weight loss mechanisms for treatment-resistant obesity.
Lang, Henry; Dorand, Madisen F; Hassan, Mahnooor; Richards, Jesse R ·
RPEP-15483 · 2026Systems biology + generative AI integration: enables multi-scale bacterial vulnerability analysis, de novo AMP design with predicted activity, and pre-synthesis resistance prediction for next-generation antimicrobials.
Lastra, José M Pérez de la; Sobrino, Isidro; Rodríguez Borges, Víctor M; de la Fuente, José ·
RPEP-15484 · 2026GLP-1 RA: improved outcomes and reduced complications after elective abdominal surgery, extending perioperative benefits to this common surgical category.
Lauck, Bradley J; Colson, Charles B; Bank, Nicholas C; Trasolini, Nicholas A; Waterman, Brian R; Churchill, Jessica; Reynolds, Alan W ·
RPEP-15486 · 2026The review identifies LAB-derived bacteriocins as promising antimicrobial agents against MDR neonatal sepsis pathogens, with several key advantages: narrow-spectrum activity that spares beneficial microbiota, biocompatibility particularly important for immunocompromised newborns, and favorable physicochemical properties including thermal stability, enzymatic resistance, and pH tolerance. Milk-derived LAB strains are highlighted as particularly relevant given breast milk's natural protective functions for newborns. Current evidence is primarily in vitro, with clinical trials needed.
Laxmi, Vijay; Verma, Sheetal; Kumar, Manoj; Venkatesh, Vimala; Mohit; Maury, Jayhind; Mohd, Shayan; Tripathi, Shalini ·